Wednesday, May 28, 2014
Tramadol pathway summary published in PG&G
Tramadol is a centrally acting opioid analgesic used to relieve moderate to severe pain. It is administered as a racemic mixture of (+) and (-) enantiomers and exerts its analgesic effect via activating the µ-opioid receptor and inhibiting the neurotransmitter reuptake. Tramadol metabolism to its major active metabolite O-desmethyl tramadol (M1) is predominantly mediated via CYP2D6. Genetic variations of CYP2D6 have been shown to affect not only the pharmacokinetics of tramadol and M1, but also the analgesic efficacy as well as pharmacodynamic responses.
We have published the
PharmGKB summary: tramadol pathway in the Pharmacogenetics and Genomics Journal. This review summarizes the metabolism and transport of tramadol and discusses genetic variations affecting the pharmacokinetics, efficacy and toxicity of tramadol and their clinical significance.
Find out more...
View our Tramadol pathway on PharmGKB.
Read our new publication:
PharmGKB summary:tramadol pathway
Gong L, Stamer UM, Tzvetkov MV, Altman RB, Klein TE.
Pharmacogenet Genomics. 2014 May 20. [Epub ahead of print]
View all pathways on PharmGKB.